Roche’s obinutuzumab (GA101) delayed disease progression longer than MabThera/Rituxan in people with one of the most common forms of blood cancer
24 July 2013 | By Roche
Results from the phase III CLL11 study...
List view / Grid view
24 July 2013 | By Roche
Results from the phase III CLL11 study...
22 July 2013 | By Roche
Roche invites 100 students from all over Europe to the Salzburg Festival...
19 July 2013 | By Roche
Tests support long-term routine management of organ transplant recipients...
18 July 2013 | By Roche
Roche announced the global launch of Elecsys ProGRP...
15 July 2013 | By Roche
The European Commission has granted conditional approval to Erivedge...
10 July 2013 | By Roche
"The safety of patients is our first priority..."
3 July 2013 | By Roche
FDA decision on the GA101 BLA is expected by the end of 2013...
2 July 2013 | By Roche
The U.S. FDA has accepted the company’s sBLA for the use of a Perjeta®...
2 July 2013 | By Roche
Strengthening Roche's commitment to hematology testing...
28 June 2013 | By Roche
"Over the last 14 years, Herceptin has revolutionised the treatment of HER2-positive breast cancer..."
17 June 2013 | By Roche
First approval of Avastin for the treatment of newly diagnosed glioblastoma...
13 June 2013 | By Roche
Roche announced data from two phase III studies...
10 June 2013 | By Roche
“This approval comes earlier than expected, just one month following the positive CHMP opinion...”
2 June 2013 | By Roche
Results of study GOG240...
1 June 2013 | By Roche
Final results from the phase III AVAglio study...